---
published: true
---


## Reviews

- CAR T Cell Therapy for Solid Tumors (Annual Review of Medicine). 

- Chimeric antigen receptor T cell therapy: 25years in the making. (Blood Rev. 2016)

- 


## Foundational Papers



## Clinical Data and Results 



## Next-Generation Approaches


### Wendell Lim's Lab: Focusing on Synthetic Biology to Control T-Cells

**URL:** http://limlab.ucsf.edu/research.html

- Design principles of regulatory networks: searching for the molecular algorithms of the cell (Mol. Cell, 2013).

- Cell-based therapeutics: the next pillar of medicine (Science Trans. Med 2013).

- Designing customized cell signaling circuits (Nature Rev. Mol. Cell Bio. 2010).

- Engineering Therapeutic T cells: From Synthetic Biology to Clinical Trials. (Annu Rev Pathol. 2017 )

- CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. (Scientific Reports. 2017)

- The Principles of Engineering Immune Cells to Treat Cancer. (Cell 2017).

- Engineering T cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. (Cell. 2016)

- Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. (Cell. 2016).

- Engineering customized cell sensing and response behaviors using synthetic notch receptors. (Cell. 2016). 

- Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. (Science. 2015).

- Synthetic biology approaches to engineer T cells. (Current Opinion in Immunology. 2015)

- Complex transcriptional modulation with orthogonal and inducible dCas9 regulators. (Nat Methods. 2016)

- Engineering dynamical control of cell fate switching using synthetic phospho-regulons. (Proceedings of the National Academy of Sciences. 2016)


### Kill-switches and Other Control Elements!

### Cell Therapies in Other Hematological Indications

- Chimeric antigen receptor T cell therapy in AML: How close are we? (Best Pract Res Clin Haematol. 2016). 

- Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells (Blood 2017).

- Pilot Study of Non-Viral, RNA-Redirected Autologous Anti-CD19 Chimeric Antigen Receptor Modified T-Cells in Patients with Refractory/Relapsed Hodgkin Lymphoma (HL) (Blood 2017). 

- CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL. (JCO 2017).




### Cell Therapies in Solid Tumors


